Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
21
04
2020
accepted:
21
12
2020
pubmed:
16
2
2021
medline:
28
9
2021
entrez:
15
2
2021
Statut:
ppublish
Résumé
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy, and many prognostic factors that influence survival remain undefined. Individually, the GRAS (Grade, Resection status, Age, and Symptoms of hormone hypersecretion) parameters have demonstrated their prognostic value in ACC. This study aimed to assess the value of a cumulative GRAS score as a prognostic indicator after ACC resection. A retrospective cohort study of adult patients who underwent surgical resection for ACC between 1993 and 2014 was performed using the United States Adrenocortical Carcinoma Group (US-ACCG) database. A sum GRAS score was calculated for each patient by adding one point each when the criteria were met for tumor grade (Weiss criteria ≥ 3 or Ki67 ≥ 20%), resection status (micro- or macroscopically positive margin), age (≥ 50 years), and preoperative symptoms of hormone hypersecretion (present). Overall survival (OS) and disease-free survival (DFS) by cumulative GRAS score were analyzed by the Kaplan-Meier method and log-rank test. Of the 265 patients in the US-ACCG database, 243 (92%) had sufficient data available to calculate a cumulative GRAS score and were included in this analysis. The 265 patients comprised 23 patients (10%) with a GRAS of 0, 52 patients (21%) with a GRAS of 1, 92 patients (38%) with a GRAS of 2, 63 patients (26%) with a GRAS of 3, and 13 patients (5%) with a GRAS of 4. An increasing GRAS score was associated with shortened OS (p < 0.01) and DFS (p < 0.01) after index resection. In this retrospective analysis, the cumulative GRAS score effectively stratified OS and DFS after index resection for ACC. Further prospective analysis is required to validate the cumulative GRAS score as a prognostic indicator for clinical use.
Sections du résumé
BACKGROUND
BACKGROUND
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy, and many prognostic factors that influence survival remain undefined. Individually, the GRAS (Grade, Resection status, Age, and Symptoms of hormone hypersecretion) parameters have demonstrated their prognostic value in ACC. This study aimed to assess the value of a cumulative GRAS score as a prognostic indicator after ACC resection.
METHODS
METHODS
A retrospective cohort study of adult patients who underwent surgical resection for ACC between 1993 and 2014 was performed using the United States Adrenocortical Carcinoma Group (US-ACCG) database. A sum GRAS score was calculated for each patient by adding one point each when the criteria were met for tumor grade (Weiss criteria ≥ 3 or Ki67 ≥ 20%), resection status (micro- or macroscopically positive margin), age (≥ 50 years), and preoperative symptoms of hormone hypersecretion (present). Overall survival (OS) and disease-free survival (DFS) by cumulative GRAS score were analyzed by the Kaplan-Meier method and log-rank test.
RESULTS
RESULTS
Of the 265 patients in the US-ACCG database, 243 (92%) had sufficient data available to calculate a cumulative GRAS score and were included in this analysis. The 265 patients comprised 23 patients (10%) with a GRAS of 0, 52 patients (21%) with a GRAS of 1, 92 patients (38%) with a GRAS of 2, 63 patients (26%) with a GRAS of 3, and 13 patients (5%) with a GRAS of 4. An increasing GRAS score was associated with shortened OS (p < 0.01) and DFS (p < 0.01) after index resection.
CONCLUSION
CONCLUSIONS
In this retrospective analysis, the cumulative GRAS score effectively stratified OS and DFS after index resection for ACC. Further prospective analysis is required to validate the cumulative GRAS score as a prognostic indicator for clinical use.
Identifiants
pubmed: 33586069
doi: 10.1245/s10434-020-09562-8
pii: 10.1245/s10434-020-09562-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6551-6561Subventions
Organisme : NCI NIH HHS
ID : F32 CA236309
Pays : United States
Organisme : NCI NIH HHS
ID : F32 CA236309
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States. Cancer. 2008;113:3130–6. https://doi.org/10.1002/cncr.23886 .
doi: 10.1002/cncr.23886
pubmed: 18973179
Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94:1853–78. https://doi.org/10.1210/jc.2008-2291 .
doi: 10.1210/jc.2008-2291
pubmed: 19494161
pmcid: 5393375
Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma. Cancer. 2008;115:243–50. https://doi.org/10.1002/cncr.24030 .
doi: 10.1002/cncr.24030
Kebebew E, Reiff E, Duh Q-Y, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872–8. https://doi.org/10.1007/s00268-005-0329-x .
doi: 10.1007/s00268-005-0329-x
pubmed: 16680602
Lughezzani G, Sun M, Perrotte P, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46:713–9. https://doi.org/10.1016/j.ejca.2009.12.007 .
doi: 10.1016/j.ejca.2009.12.007
pubmed: 20044246
Gaujoux S, Weinandt M, Bonnet S, Reslinger V, Bertherat J, Dousset B. Surgical treatment of adrenal carcinoma. J Visceral Surg. 2017;154:335–43. https://doi.org/10.1016/j.jviscsurg.2017.06.010 .
doi: 10.1016/j.jviscsurg.2017.06.010
Marincola Smith P, Kiernan CM, Tran TB, et al. Role of additional organ resection in adrenocortical carcinoma: analysis of 167 patients from the U.S. Adrenocortical Carcinoma Database. Ann Surg Oncol. 2018;25:2308–15. https://doi.org/10.1245/s10434-018-6546-y .
doi: 10.1245/s10434-018-6546-y
pubmed: 29868977
Prendergast KM, Marincola Smith P, Tran TB, et al. Features of synchronous versus metachronous metastasectomy in adrenal cortical carcinoma: analysis from the US adrenocortical carcinoma database. Surgery. 2020;167:352–7. https://doi.org/10.1016/j.surg.2019.05.024 .
doi: 10.1016/j.surg.2019.05.024
pubmed: 31272813
Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169:891–9. https://doi.org/10.1530/EJE-13-0519 .
doi: 10.1530/EJE-13-0519
pubmed: 24086089
pmcid: 4441210
Libé R, Borget I, Ronchi CL, et al. Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): a European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015;26:2119–25. https://doi.org/10.1093/annonc/mdv329 .
doi: 10.1093/annonc/mdv329
pubmed: 26392430
Liang J, Liu Z, Zhou L, et al. The clinical utility of “GRAS” parameters in stage I–III adrenocortical carcinomas: long-term data from a high-volume institution. Endocrine. 2020;67(2):449–56. https://doi.org/10.1007/s12020-019-02141-2 .
Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009;40:1–12. https://doi.org/10.1016/j.humpath.2009.03.010 .
doi: 10.1016/j.humpath.2009.03.010
Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91:2650–5. https://doi.org/10.1210/jc.2005-2730 .
doi: 10.1210/jc.2005-2730
pubmed: 16670169
Volante M, Bollito E, Sperone P, et al. Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology. 2009;55:535–43. https://doi.org/10.1111/j.1365-2559.2009.03423.x .
doi: 10.1111/j.1365-2559.2009.03423.x
pubmed: 19912359
Berruti A, Fassnacht M, Haak H, et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014;65(4):832–8. https://doi.org/10.1016/j.eururo.2013.11.006 .
Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. JCO. 2002;40:941–50.
doi: 10.1200/JCO.2002.20.4.941
Edge SB, Compton CC 2010 The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4. https://doi.org/10.1245/s10434-010-0985-4 .
Miller BS, Gauger PG, Hammer GD, Giordano TJ, Doherty GM. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg. 2010;395:955–61. https://doi.org/10.1007/s00423-010-0698-y .
doi: 10.1007/s00423-010-0698-y
pubmed: 20694732
Papathomas TG, Pucci E, Giordano TJ, et al. An international Ki67 reproducibility study in adrenal cortical carcinoma. Am J Surg Pathol. 2016;40:569–76. https://doi.org/10.1097/PAS.0000000000000574 .
doi: 10.1097/PAS.0000000000000574
pubmed: 26685085
Kim Y, Margonis GA, Prescott JD, et al. Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma. JAMA Surg. 2016;151:365–73. https://doi.org/10.1001/jamasurg.2015.4516 .
doi: 10.1001/jamasurg.2015.4516
pubmed: 26676603
pmcid: 4967352
Margonis GA, Kim Y, Tran TB, et al. Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Am J Surg. 2016;211:1106–13. https://doi.org/10.1016/j.amjsurg.2015.09.020 .
doi: 10.1016/j.amjsurg.2015.09.020
pubmed: 26810939
Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, et al. Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab. 2018;103:4511–23. https://doi.org/10.1210/jc.2018-01348 .
doi: 10.1210/jc.2018-01348
pubmed: 30113656